All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

lovastatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors	1612	75330-75-5

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: lovastatin lostatin mevacor

A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. Molecular weight: 404.55 Formula: C24H36O5 CLOGP: 4.08 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 72.83 ALOGS: -4.22 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
45	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.29 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1	22
kinase-selectivity-class	AXL,GRK2	2
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.513		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		High	1
rat-kpuu-brain	Rat brain Kpuu	0.805	%	High	1

Approvals:

Date	Agency	Company	Orphan
Aug. 31, 1987	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	73.11	12.67	136	20047	174989	90433275
Cardiac failure congestive	72.12	12.67	99	20084	98595	90509669
Contraindicated product administered	55.89	12.67	4	20179	320135	90288129
Synovitis	55.12	12.67	5	20178	329747	90278517
Infusion related reaction	54.42	12.67	13	20170	416767	90191497
Systemic lupus erythematosus	54.25	12.67	8	20175	361888	90246376
Blood glucose increased	52.92	12.67	84	20099	95162	90513102
Atrial fibrillation	49.88	12.67	99	20084	133512	90474752
Glossodynia	48.48	12.67	7	20176	321772	90286492
Rhabdomyolysis	47.75	12.67	58	20125	51198	90557066
Dehydration	41.74	12.67	116	20067	194331	90413933
General physical health deterioration	39.25	12.67	15	20168	355100	90253164
Lower respiratory tract infection	38.82	12.67	5	20178	250654	90357610
Exposure during pregnancy	38.81	12.67	4	20179	238406	90369858
Wound	38.46	12.67	10	20173	302970	90305294
Myocardial infarction	37.73	12.67	77	20106	105895	90502369
Hepatic enzyme increased	35.51	12.67	18	20165	360718	90247546
Treatment failure	35.00	12.67	12	20171	303916	90304348
Irritable bowel syndrome	32.46	12.67	4	20179	207444	90400820
Drug hypersensitivity	31.82	12.67	194	19989	463415	90144849
Feeling abnormal	30.35	12.67	94	20089	167141	90441123
Cerebrovascular accident	29.82	12.67	77	20106	123456	90484808
C-reactive protein increased	29.63	12.67	3	20180	181386	90426878
Coronary artery disease	29.62	12.67	37	20146	33586	90574678
Asthenia	28.02	12.67	209	19974	533542	90074722
Chronic obstructive pulmonary disease	27.89	12.67	55	20128	73774	90534490
Off label use	27.14	12.67	140	20043	1102112	89506152
Fall	26.61	12.67	191	19992	481619	90126645
Product dose omission issue	25.96	12.67	131	20052	291556	90316708
Alopecia	25.94	12.67	44	20139	495027	90113237
Death	24.64	12.67	180	20003	456371	90151893
Rheumatoid arthritis	24.25	12.67	27	20156	362587	90245677
Arthropathy	23.70	12.67	28	20155	366214	90242050
Product use issue	22.68	12.67	24	20159	329895	90278369
Drug intolerance	22.34	12.67	41	20142	447550	90160714
Retroperitoneal oedema	21.86	12.67	4	20179	24	90608240
Nausea	21.31	12.67	356	19827	1109960	89498304
Discomfort	21.14	12.67	18	20165	274317	90333947
Impaired healing	21.13	12.67	13	20170	234186	90374078
Liver injury	20.94	12.67	6	20177	170561	90437703
Myopathy	20.89	12.67	20	20163	13498	90594766
Muscle spasms	20.25	12.67	110	20073	251773	90356491
Pyrexia	19.73	12.67	78	20105	660407	89947857
Chronic kidney disease	19.70	12.67	38	20145	50153	90558111
Abdominal discomfort	19.44	12.67	49	20134	477279	90130985
Type 2 diabetes mellitus	18.73	12.67	11	20172	203233	90405031
Febrile neutropenia	18.66	12.67	6	20177	158343	90449921
Amyotrophic lateral sclerosis	18.56	12.67	8	20175	1340	90606924
Urinary tract infection	18.52	12.67	124	20059	305508	90302756
Fatigue	18.26	12.67	359	19824	1153664	89454600
Back pain	17.64	12.67	126	20057	317049	90291215
Therapeutic product effect decreased	17.13	12.67	22	20161	277549	90330715
Cardiomegaly	16.95	12.67	21	20162	18904	90589360
Dizziness	16.92	12.67	203	19980	589081	90019183
Joint swelling	16.62	12.67	57	20126	503243	90105021
Gastrointestinal haemorrhage	16.61	12.67	51	20132	90197	90518067
Visual acuity reduced	16.36	12.67	23	20160	23387	90584877
Joint range of motion decreased	16.23	12.67	5	20178	135638	90472626
Hypersensitivity	16.04	12.67	50	20133	454627	90153637
Ill-defined disorder	15.68	12.67	11	20172	184880	90423384
Hypoglycaemia	15.29	12.67	42	20141	69806	90538458
Pulmonary arterial pressure increased	15.27	12.67	10	20173	3906	90604358
Psoriatic arthropathy	15.25	12.67	17	20166	228318	90379946
Swelling	14.84	12.67	46	20137	419012	90189252
Renal failure	14.70	12.67	63	20120	130944	90477320
Oedema peripheral	14.64	12.67	103	20080	257812	90350452
Urinary incontinence	14.20	12.67	28	20155	37538	90570726
Mental status changes	14.19	12.67	31	20152	44648	90563616
Fibromyalgia	14.17	12.67	15	20168	206254	90402010
Withdrawal syndrome	14.09	12.67	21	20162	22503	90585761
Injury	13.96	12.67	14	20169	197335	90410929
Hypoxic-ischaemic encephalopathy	13.68	12.67	10	20173	4658	90603606
Nervousness	13.63	12.67	26	20157	34030	90574234
Gait disturbance	13.62	12.67	102	20081	260394	90347870
Inflammation	13.41	12.67	12	20171	178580	90429684
Gallbladder oedema	13.20	12.67	4	20179	243	90608021
Blood urea increased	13.14	12.67	24	20159	30389	90577875
Hip fracture	12.92	12.67	25	20158	33052	90575212
Blood potassium decreased	12.82	12.67	31	20152	47696	90560568
Blood cholesterol abnormal	12.81	12.67	8	20175	2882	90605382

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myasthenic syndrome	48.91	13.82	16	14616	805	42605898
Rhabdomyolysis	44.79	13.82	89	14543	77930	42528773
Cardiac failure congestive	41.37	13.82	91	14541	85511	42521192
Off label use	38.85	13.82	103	14529	638232	41968471
Myalgia	38.61	13.82	95	14537	95985	42510718
Neck mass	29.94	13.82	14	14618	1836	42604867
Cerebrovascular accident	29.86	13.82	87	14545	97073	42509630
Febrile neutropenia	28.61	13.82	14	14618	185689	42421014
Myocardial infarction	25.55	13.82	97	14535	123912	42482791
Asthenia	24.77	13.82	173	14459	280620	42326083
Blood creatine phosphokinase increased	24.03	13.82	52	14580	48286	42558417
Back disorder	23.55	13.82	20	14612	7494	42599209
Diverticulum	23.49	13.82	20	14612	7521	42599182
Drug abuse	23.22	13.82	4	14628	104767	42501936
Injury	22.88	13.82	33	14599	22283	42584420
Myopathy	21.39	13.82	25	14607	13736	42592967
International normalised ratio increased	20.80	13.82	49	14583	48119	42558584
Sleep inertia	19.24	13.82	4	14628	31	42606672
Thrombocytosis	17.67	13.82	14	14618	4761	42601942
Blood glucose increased	17.15	13.82	60	14572	73639	42533064
Cardiovascular disorder	17.09	13.82	22	14610	13343	42593360
Anxiety	16.91	13.82	83	14549	118477	42488226
Completed suicide	16.31	13.82	71	14561	96394	42510309
Product use in unapproved indication	16.09	13.82	24	14608	184432	42422271
Hand deformity	16.03	13.82	12	14620	3756	42602947
Potentiating drug interaction	15.88	13.82	15	14617	6453	42600250
Vision blurred	14.52	13.82	46	14586	53653	42553050
Right ventricular failure	14.26	13.82	17	14615	9538	42597165
Pyrexia	13.89	13.82	79	14553	393963	42212740
Pinguecula	13.84	13.82	3	14629	29	42606674
Myositis	13.82	13.82	21	14611	14845	42591858

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure congestive	108.44	12.34	157	26661	150843	110411638
Rhabdomyolysis	104.20	12.34	137	26681	120264	110442217
Myalgia	78.22	12.34	169	26649	222212	110340269
Myocardial infarction	69.87	12.34	148	26670	191935	110370546
Blood glucose increased	58.86	12.34	111	26707	132385	110430096
Infusion related reaction	52.12	12.34	14	26804	381148	110181333
Cerebrovascular accident	48.67	12.34	124	26694	181160	110381321
Asthenia	47.83	12.34	308	26510	688691	109873790
Myasthenic syndrome	47.44	12.34	16	26802	1260	110561221
Off label use	46.48	12.34	197	26621	1499988	109062493
Atrial fibrillation	43.96	12.34	139	26679	229503	110332978
Myopathy	43.51	12.34	41	26777	24919	110537562
Pericarditis	41.56	12.34	3	26815	219111	110343370
General physical health deterioration	38.73	12.34	28	26790	425267	110137214
Coronary artery disease	38.15	12.34	65	26753	71625	110490856
Systemic lupus erythematosus	37.39	12.34	8	26810	254330	110308151
Dehydration	37.06	12.34	150	26668	279361	110283120
Death	36.07	12.34	291	26527	698578	109863903
Completed suicide	35.31	12.34	134	26684	242247	110320234
Lower respiratory tract infection	35.02	12.34	8	26810	243098	110319383
Treatment failure	34.61	12.34	12	26806	277222	110285259
Febrile neutropenia	34.24	12.34	17	26801	316750	110245731
Glossodynia	32.60	12.34	7	26811	221997	110340484
Drug abuse	32.06	12.34	3	26815	177408	110385073
Blood creatine phosphokinase increased	30.93	12.34	60	26758	73017	110489464
Contraindicated product administered	30.55	12.34	11	26807	248256	110314225
Renal failure	28.76	12.34	120	26698	226454	110336027
Irritable bowel syndrome	26.65	12.34	4	26814	164211	110398270
Feeling abnormal	26.38	12.34	100	26718	180611	110381870
Hand deformity	26.35	12.34	10	26808	218496	110343985
Wound	26.22	12.34	12	26806	234425	110328056
International normalised ratio increased	26.07	12.34	62	26756	86710	110475771
Fall	24.24	12.34	238	26580	603244	109959237
Muscle injury	23.87	12.34	3	26815	140804	110421677
Hypoglycaemia	23.79	12.34	72	26746	116032	110446449
Mental status changes	23.53	12.34	55	26763	76067	110486414
Plasma cell myeloma	23.44	12.34	49	26769	62887	110499594
Cardiovascular disorder	23.00	12.34	28	26790	22732	110539749
Gastrointestinal haemorrhage	22.86	12.34	90	26728	165428	110397053
Retroperitoneal oedema	21.97	12.34	4	26814	21	110562460
Neck mass	21.93	12.34	14	26804	4807	110557674
Product use in unapproved indication	21.42	12.34	48	26770	447329	110115152
Pyrexia	20.87	12.34	130	26688	898135	109664346
Liver disorder	19.85	12.34	5	26813	142238	110420243
Drug hypersensitivity	19.66	12.34	182	26636	453908	110108573
Sleep inertia	19.63	12.34	4	26814	41	110562440
Fatigue	19.60	12.34	408	26410	1215550	109346931
Chronic kidney disease	19.24	12.34	51	26767	76240	110486241
Impaired healing	19.17	12.34	12	26806	196705	110365776
Pain in extremity	19.01	12.34	191	26627	486927	110075554
C-reactive protein increased	18.98	12.34	15	26803	217904	110344577
Diverticulum	18.86	12.34	21	26797	15505	110546976
Product dose omission issue	18.78	12.34	138	26680	321644	110240837
Hypersensitivity	18.01	12.34	45	26773	403953	110158528
Rheumatoid arthritis	18.00	12.34	28	26790	299585	110262896
Intentional overdose	17.84	12.34	5	26813	132496	110429985
Vision blurred	17.68	12.34	70	26748	128952	110433529
Cardio-respiratory arrest	17.65	12.34	65	26753	115771	110446710
Blood urea increased	17.30	12.34	40	26778	54917	110507564
Right ventricular failure	17.18	12.34	26	26792	25928	110536553
Back disorder	16.84	12.34	23	26795	20899	110541582
Alopecia	16.75	12.34	40	26778	364713	110197768
Chronic obstructive pulmonary disease	16.42	12.34	61	26757	109097	110453384
Myositis	16.27	12.34	28	26790	31088	110531393
Discomfort	16.06	12.34	17	26801	214690	110347791
Inflammation	15.97	12.34	14	26804	193224	110369257
Renal injury	15.72	12.34	21	26797	18692	110543789
Hepatic enzyme increased	15.70	12.34	34	26784	320858	110241623
Bursitis	15.57	12.34	6	26812	129912	110432569
Wheezing	15.18	12.34	24	26794	255206	110307275
Epilepsy	15.03	12.34	3	26815	100206	110462275
Lung disorder	14.93	12.34	13	26805	180034	110382447
Potentiating drug interaction	14.58	12.34	16	26802	11627	110550854
Amyotrophic lateral sclerosis	14.58	12.34	8	26810	2083	110560398
Therapeutic product effect decreased	14.51	12.34	23	26795	244293	110318188
Arthropathy	14.45	12.34	30	26788	287492	110274989
Drug intolerance	14.01	12.34	51	26767	406461	110156020
Oedema peripheral	13.85	12.34	131	26687	328529	110233952
Migraine	13.51	12.34	13	26805	171639	110390842
Blood creatinine increased	13.40	12.34	83	26735	182806	110379675
Fibromyalgia	13.39	12.34	13	26805	170896	110391585
Psoriatic arthropathy	13.19	12.34	17	26801	196744	110365737
Product use issue	12.91	12.34	36	26782	311659	110250822
Corneal deposits	12.86	12.34	5	26813	591	110561890
Postmenopausal haemorrhage	12.70	12.34	7	26811	1839	110560642
Coronary artery bypass	12.64	12.34	11	26807	6031	110556450
Gastrointestinal injury	12.50	12.34	7	26811	1896	110560585
Back pain	12.37	12.34	141	26677	370855	110191626

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AA02	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors
ATC	C10BA01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
FDA MoA	N0000000121	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D000924	Anticholesteremic Agents
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019161	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D057847	Lipid Regulating Agents
FDA EPC	N0000175589	HMG-CoA Reductase Inhibitor
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35821	anticholesteremic drug
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:50266	prodrug
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:76956	<em>Aspergillus </em> metabolite
CHEBI has role	CHEBI:145947	antiatherosclerotic agent

Related Drugs by ATC class:

C10AA HMG CoA reductase inhibitors 7 drugs

atorvastatincerivastatinfluvastatinpitavastatinpravastatinrosuvastatinsimvastatin

C10BA Combinations of various lipid modifying agents 9 drugs

atorvastatinbempedoic acidezetimibefenofibratenicotinic acidpitavastatinpravastatinrosuvastatinsimvastatin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Arteriosclerotic vascular disease	indication	72092001
Hypoalphalipoproteinemia	indication	190785000
Familial hypercholesterolemia - heterozygous	indication	238079002
Mixed hyperlipidemia	indication	267434003
Hypertriglyceridemia	indication	302870006
Myocardial Reinfarction Prevention	indication
Slow Progression of Coronary Artery Disease	indication
Primary Prevention of Coronary Heart Disease	indication
Myocardial Infarction Prevention	indication
Cerebrovascular accident	off-label use	230690007
Prevention of Transient Ischemic Attacks	off-label use
Hypophosphatemia	contraindication	4996001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Myocardial infarction	contraindication	22298006	DOID:5844
Low blood pressure	contraindication	45007003
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Gout	contraindication	90560007	DOID:13189
Disorder of muscle	contraindication	129565002	DOID:423
Liver function tests abnormal	contraindication	166603001
Hemorrhagic cerebral infarction	contraindication	230706003
Arterial hemorrhage	contraindication	234003006
Disease of liver	contraindication	235856003	DOID:409
Rhabdomyolysis	contraindication	240131006
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Surgical procedure	contraindication	387713003
Acute coronary syndrome	contraindication	394659003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Traumatic injury	contraindication	417746004
Uncontrolled Epilepsy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme	P04035	HMDH_HUMAN	INHIBITOR	IC50	7.67		WOMBAT-PK	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.10		DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	4.81		DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN	AGONIST	EC50	6		IUPHAR
Hydroxycarboxylic acid receptor 2	GPCR	Q8TDS4	HCAR2_HUMAN		IC50	7.30		WOMBAT-PK
Hydroxycarboxylic acid receptor 3	GPCR	P49019	HCAR3_HUMAN		IC50	6.53		WOMBAT-PK
Histone deacetylase 2	Enzyme	Q92769	HDAC2_HUMAN		IC50	4.59		CHEMBL
Histone deacetylase 1	Enzyme	Q13547	HDAC1_HUMAN		IC50	4.92		CHEMBL
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN		IC50	4.79		CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.03		DRUG MATRIX
Leukocyte adhesion glycoprotein LFA-1 alpha	Adhesion	P20701	ITAL_HUMAN		Kd	4.89		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.06		DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.70		DRUG MATRIX
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	5.57		CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_RAT		IC50	8.52		CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_MOUSE		IC50	7.57		CHEMBL
Cholinesterase	Enzyme		CHLE_HORSE		Ki	5.96		CHEMBL
Acyl-CoA:cholesterol acyltransferase	Enzyme		Q95214_RABIT		IC50	4.77		CHEMBL

External reference:

ID	Source
4019482	VUID
N0000147602	NUI
D00359	KEGG_DRUG
4019482	VANDF
C0024027	UMLSCUI
CHEBI:40303	CHEBI
803	PDB_CHEM_ID
CHEMBL503	ChEMBL_ID
D008148	MESH_DESCRIPTOR_UI
DB00227	DRUGBANK_ID
53232	PUBCHEM_CID
2739	IUPHAR_LIGAND_ID
6074	INN_ID
9LHU78OQFD	UNII
224938	RXNORM
1105	MMSL
42628	MMSL
4998	MMSL
d00280	MMSL
002063	NDDF
386024001	SNOMEDCT_US
96303004	SNOMEDCT_US
9LHU78OQFD	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0576	TABLET	20 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0926	TABLET	10 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0928	TABLET	40 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8151	TABLET	20 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8152	TABLET	40 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-235	TABLET	10 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-241	TABLET	20 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-242	TABLET	40 mg	ORAL	ANDA	22 sections
Lovastatin	Human Prescription Drug Label	1	10544-246	TABLET	20 mg	ORAL	ANDA	19 sections
LOVASTATIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-311	TABLET	10 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-534	TABLET	10 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-535	TABLET	20 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-536	TABLET	40 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	33261-547	TABLET	10 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	33261-548	TABLET	20 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	33261-549	TABLET	40 mg	ORAL	ANDA	22 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-025	TABLET	40 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-028	TABLET	20 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-106	TABLET	10 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-493	TABLET	10 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-548	TABLET	40 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-692	TABLET	20 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-939	TABLET	40 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43063-983	TABLET	20 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	43353-763	TABLET	40 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0759	TABLET	20 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0761	TABLET	40 mg	ORAL	ANDA	21 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0762	TABLET	40 mg	ORAL	ANDA	12 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3216	TABLET	40 mg	ORAL	ANDA	23 sections
Lovastatin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3268	TABLET	10 mg	ORAL	ANDA	23 sections